Calculating risk in glaucoma

Article

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Michael V. Boland, MD, PhD of Johns Hopkins University, Baltimore, US and colleagues used the Ocular Hypertension Treatment Study to create two scenarios with equal risk of glaucoma development, only one of which included an estimate of glaucoma risk. The team then asked glaucoma specialists to review the scenarios and make treatment recommendations, and compared the differences in these recommendations based on whether glaucoma risk had previously been identified.

The researchers found that the presence of the glaucoma risk calculator increased the specialists' confidence and consistency in their own treatment recommendations. The physicians evaluated risk factors differently based on the presence or absence of the risk calculator.

Thus the researchers concluded that presence of a risk calculator altered treatment recommendations to the extent that specialists were more reassured about their recommendations when a risk calculator was available.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.